Dr. Oslin receives grant support from the NIH, VA, and the Pennsylvania Department of Aging.

Similar documents
Addiction Medicine: What s new for primary care

THE STATE OF MEDICINE IN ADDICTION RECOVERY

GUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS

8/5/2013. MOSBIRT Annual Training The Big change in addiction medicine? Before we dive into pharmacotherapy

POLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE

Treatment Approaches for Drug Addiction

Treatment Alternatives for Substance Use Disorders

SUBSTANCE ABUSE IN THE ELDERLY. The Invisible Epidemic

Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines

Aging and Addiction:

Dr. Renner receives honoraria from Reed Medical Education

10 INDEX Acknowledgements, i

Health Systems and Addiction: Provider Issues

Treatment Team Approaches in Substance Abuse Treatment

Alcohol Use in the Elderly

Medication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs

Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry

RECOMMENDATIONS FOR HEALTH CARE PROVIDERS

Substance Misuse in Older People

Intro to Concurrent Disorders

Biological Addictions Treatment. Psychology 470. Many Types of Approaches

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE

Psychopharmacology Practice Guidelines For Individuals With Co-Occurring Substance Abuse (SA) And Serious Mental Illness (SMI)

Medications For Alcohol Use Disorder. DATE: October 10, 2017 PRESENTED BY: Alann Weissman-Ward, MD, Addiction Medicine fellow

Management of high risk MMT patients. Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013

Prevention & Older Adults: Don t You Forget About Us!

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

^ PRIMER OF DRUG ACTION A comprehensive gyide to the actions, uses, and side effects of psychoactive drugs

Medications For Alcohol Use Disorder

Opiate Use Disorder and Opiate Overdose

Pharmacotherapy for Substance Use Disorders

Long term pharmacotherapy for Alcohol Dependence: Anti Craving agents

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

David Bienenfeld, M.D. Wright State University Department of Psychiatry

Acute General Medical and Surgical Admission:

Integrating MH/SA Treatment in Primary Care Firm Clinics: The Behavioral Health Clinic

Medical vs. Use of Drugs. Warning Signs of Chemical Dependence. Intent Effect. Legality Pattern 5/5/2010. Daily use above ceiling doses

Basics of Benzodiazepine Use Disorder. DATE: June 12, 2018 PRESENTED BY: Melissa B. Weimer, DO, MCR

NURSING FOLLOW-UP: BUPRENORPHINE/NALOXONE BUPRENORPHINE/NALOXONE CLINIC VISITS

Medication for Addiction Treatment (MAT)

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

BASIC VOLUME. Elements of Drug Dependence Treatment

NIDA Principles of Treatment. NIDA Principles of Treatment. Peter Banys, M.D., M.Sc. No single treatment is appropriate for all individuals.

Thaddeus Ulzen MD FRCP(C)FAPA FCGP Professor & Chair, Department of Psychiatry and Behavioral Medicine, Associate Dean for Academic Affairs

ROLE OF HEALTH CARE PROVIDERS IN THE MANAGEMENT OF ALCOHOL AND DRUG USE RELATED PROBLEMS

Start Low, Go Slow but Treat to Target

Naltrexone protocol alcohol

REVIEW ARTICLE MANAGEMENT OF PATIENTS WITH MOOD DISORDERS AND COMORBID SUDS

THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept.

Goal: To learn about and evaluate the value of various biologically-based methods in the treatment of different forms of psychopathology

Methadone Maintenance 101

Restoration of Parenting Ability Through Treatment for Substance Use Disorders

DRUGS USED IN THE TREATMENT OF ADDICTION JOSEPH A. TRONCALE, MD FASAM RETREAT PREMIERE ADDICTION TREATMENT CENTERS

Objectives 11/2/2016. Managing Patients with Substance Abuse. Off Label Disclosure. Steven Shoptaw, PhD Professor Department of Family Medicine, UCLA

The future of pharmacological treatment.

Serious Mental Illness and Opioid Use Disorder

What I Want From Treatment User Information

Characteristics of MST Are Similar to Complex Trauma

The OAS Report. Issue Suicidal Thoughts, Suicide Attempts, Major Depressive Episode, and Substance Use among Adults.

Addressing the Opioid Epidemic in the Veterans Health Administration

Managing drug misuse in pregnancy and beyond

BAPTIST HEALTH SCHOOL OF NURSING NSG 3036A: PSYCHIATRIC-MENTAL HEALTH

Pain and Addiction. Edward Jouney, DO Department of Psychiatry

Effective Treatment of Depression in Older African Americans: Overcoming Barriers

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.

1/26/2016. These are my own thoughts! Safe Workplace Safe Workforce Proven benefits of Stay At Work / Return To Work Process (SAW/RTW)

PITTSBURGH MERCY: COMPREHENSIVE INTEGRATED CARE JUNE 6, 2018

Basics of Benzodiazepine Use Disorder. DATE: October 3, 2017 PRESENTED BY: Melissa B. Weimer, DO, MCR

MEDICATION ASSISTED ADDICTION TREATMENT: Appropriate Use

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D.

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates

The Importance of Psychological Treatment and Behavioral Support

Substance Use Disorders in Primary Care

IDDT Fidelity Action Planning Guidelines

Depression & Alcohol

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

The Use, Misuse and Abuse of Alcohol, and Psychoactive Drugs among Older Persons

Bipolar Disorder Clinical Practice Guideline Summary for Primary Care

Page 1. Pharmacologic Interventions for. Addictions. Objectives for This Talk. Outline for This Talk

Pharmacologic Interventions for. Addictions

Basics of Benzodiazepine Use Disorder. DATE: March 20, 2018 PRESENTED BY: Melissa B. Weimer, DO, MCR

Alcoholism has been demonstrated to have a genetic component, especially among men.

Rational prescribing in the older adult. Assoc Prof Craig Whitehead

Medical Management of Substance Use Disorders: Does research translate to clinical practice

The Treatment of Addiciton in Older Adults

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings

Tianeptine Dependence: A Case Report

Substance Use Prevalence. Source: 2012 SAMHSA NSDUH

Substance Use Disorders. A Major Problem. Defining Addiction 2/24/2009. Lifetime rates of alcoholism estimated at 13.4 %

Conor K Farren. St Patricks University Hospital Trinity College Dublin Ireland

DAWN. In 2009, nearly 4.6 million emergency

In 2009, nearly 4.6 million emergency

Opioid dependence and buprenorphine treatment

Pharmacotherapy of Substance Use Disorders in Children and Adolescents: Special Considerations

Outline. Who are the elderly? Older Adults and Alcohol Problems

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center

MEDICATION ALGORITHM FOR ANXIETY DISORDERS

Managing Patients With Substance Use Disorders: A Case-Based Approach

Transcription:

David W. Oslin, MD University of Pennsylvania Philadelphia VAMC Dr. Oslin receives grant support from the NIH, VA, and the Pennsylvania Department of Aging. Dr. Oslin is a consultant to the Hazelden Betty Ford Foundation. Dr. Oslin has consulted for Otsuka Pharmaceuticals 1

13 percent of U.S. population age 65+; expected to increase up to 20 percent by 2030 78 million Baby Boomers (born from 1946-1964) in U.S. Census 2000 Second wave Baby Boomers (now aged 35-44) contains 45 million Baby Boomers are currently 50-68 years old Major pressure on retirement systems, health care facilities, and other services Enormous implications for substance abuse and mental health prevention and treatment The number of adults with substance use disorders is projected to double from 2.8 million (annual average) in 2002-2006 to 5.7 million in 2020. (Han et al, 2009) The Good More assets Healthier Less stigma Better educated The Bad Quick fix generation Greater opportunities The Ugly Illicit substance exposure and use Pharmaceutical misuse 2

Most common addictions: Nicotine: ~ 18 22 percent Alcohol: ~ 2 18 percent Psychoactive Prescription Drugs: ~ 2 4 percent Other illegal drugs (marijuana, cocaine, narcotics): <1 percent At least one in five (19%) older adults use psychoactive medications with abuse potential (Simoni-Wastila, Yang, 2006) 11% of women > 60 years old misuse prescription medication (Simoni- Wastila, Yang, 2006) 18-41% of older adults are affected by medication misuse (Office of Applied Studies, SAMHSA, 2004) Antidepressant (n=263 (60%)) Anxiolytic (n=143 (33%)) Antipsychotic (n=33 (8%)) Sociodemographic Characteristics Age (Mean, SD) 79 (7) 79 (7) 80 (7) Low Overall Symptomatology 45% 56% 30% 9 3

M:W p= 0.0393, Positive: Negative p=0.002 10 ADRs per 10,000 Population 60 50 40 30 20 10 0 1 (infancy) 20-29 40-49 60-69 80+ Age (y) Ghose K. Drugs Aging. 1991;1:2-5. 11 Nolan L, O Malley K. Age Ageing. 1989;18:52-56. 12 4

Older adults are three times as likely to develop a mental disorder with a lifetime diagnosis of alcohol abuse. Common Dual Diagnoses include: Depression (20-30%) Cognitive loss (10-40%) Anxiety disorders (10-20%) Sleep Disorders Longitudinal study of nursing home residents with Alcohol related dementia (n=16) or Alzheimer s Disease (n=26). Subjects identified from consecutive nursing home admissions (n=212) evaluated for cognition, disability, addiction history Subjects followed every 6 months for 2 years. (Oslin, et. al. 2003) P=0.006 5

Alcohol abuse more prevalent in older persons who are separated, divorced, or widowed Highest rates of completed suicides: Older white males who are depressed, drinking heavily, and who have recently lost their partner or spouse 6

Benzodiazepines Doses are lower and toxicity greater Alprazolam or oxazepam Others (chlordiazepoxide, diazepam, etc) Gabapentin 400 mg t.i.d. for 3 days, 400 mg b.i.d. for 1 day, 400 mg for 1 day. Clinicians view low engagement (<40%) non-adherence poor prognosis high drop out rates (~70%) Patient view <20% report getting the help they need >80% report a desire to change Often only exposed to 1 or 2 types of treatment 20 Addiction Health Musculoskeletal health Chronic Pain Sexuality Social structure Time management Cognition Life stage generativity and purpose Suicidality and death ideation 7

Brain changes Decrease cortical neurons Decreased blood flow 15-20% Increased sensitivity to medications (alcohol, anticholinergic, etc) Sensory changes Visual and hearing loss Olfactory changes Liver changes General but variable decrease in hepatic blood flow limits first pass metabolism Drugs with large 1 st pass metabolism increase in concentration (e. g. opiates) Decrease reduction, oxidation, and hydrolysis Drugs may accumulate barbiturates and long acting benzodiazepines Short acting Benzo s are conjugated which is not affected by age 22 Pharmacotherapy Compliance with treatment is greater in older adults compared to younger adults. Age appropriate treatment planning is critical. 8

Elderly Subjects Middle Aged Attend AA 81.2 91.1 Have a sponsor 54.6 64.7 Attend Aftercare 31.2 56.4 Things to Avoid Reliance only on peer support Simple referral Treat concurrent disorder alone Abstinence as the only acceptable outcome Be careful about groups without context Things to Learn CBT or other evidenced based psychotherapy Pharmacotherapy Patients may have different goals than you Toxicity is often dose dependent. Strive for the lowest dose possible. The domains of care need to take into age appropriate domains Alcohol dependence Naltrexone Acamprosate Antabuse Topiramate Opioids Buprenorphine Methadone Naltrexone Cocaine? Nicotine Nicotine replacement Bupropion Verenicline Antidepressants Mood Stabilizers Antipsychotics Benzodiazepines Sleep enhancers Cognitive Enhancers Stimulants Serotonergic agents 9

Prior treatment failure Presence of craving, stimulation, or reward High level of interest in biomedical therapies Low level of interest in traditional psychosocial therapies or settings Cognitive impairment In most alcohol-dependent patients Consider depot formulation for added adherence Oslin DW, et al. American Journal of Geriatric Psychiatry 10: 740-747, 2002. Mechanism of action is unknown GABA vs NMDA Low rate of adverse effects Usual dose 2 gm/d divided 4 times/day No trials specifically in older adults Caution to watch for patients with renal failure 30 10

Not directly addressing addiction Universally effective Easy to stop Limited efficacy trials No trials specifically in older adults Disulfiram reaction may be more problematic in older adults. 31 32 By all accounts serotonin is important in addictions But results from treatment trials? Some say yes, some say no, others maybe. SSRI s are not proven in older adults most trials are negative Side effects are not uncommon and often lead to use of benzo s 33 11

Methadone Naltrexone Buprenorphine and Buprenorphine/Naloxone Partial agonist Office based treatment but need to take a training course No studies in older adults CSAP TIPS Series: http://www.treatment.org/externals/tips.html and http://www.samhsa.gov TIP #26 Older Adults Fleming, Barry, Manwell, Johnson, London (1997). Brief physician advice for problem alcohol drinkers. Journal of the American Medical Association, 277, 1039-1080. Barry, Oslin, Blow (2001) Prevention and Management of Alcohol Problems in Older Adults. New York, Springer Publishing. Oslin DW, Pettinati H, and Volpicelli JR, Alcoholism treatment adherence: older age predicts better adherence and drinking outcomes. American Journal of Geriatric Psychiatry., 2002. 10: p. 740-7. 12